Foundayo ex-U.S. launch wave: Mexico and Saudi Arabia next, with most international launches in 2027.
Foundayo U.S. type 2 diabetes indication: completed submission and expected regulatory action later in 2026.
Retatrutide U.S. regulatory submission planned for Q1 2027 under the BLA pathway.
Medicare GLP-1 Bridge program creates a new $50-per-month U.S. access channel for obesity medicines.
First dedicated genetic medicine manufacturing facility in Lebanon, Indiana comes online.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Eli Lilly and Company and 4,900+ companies.